Everest Medicines commissions mRNA vaccine production plant in Jiashan

TAGS

Everest Medicines, a China-based biopharmaceutical company, has commenced operations at its mRNA vaccine production plant in Jiashan, Zhejiang Province, thereby becoming a fully-integrated biopharma.

With the first phase going live, Everest Medicines now owns complete pharmaceutical and vaccine value chain from discovery, clinical development, manufacturing, and commercialization.

The first phase of the vaccine manufacturing facility in Jiashan spans over an area of 58,000 square meters and can manufacture 700 million doses of mRNA vaccines per annum.

See also  Bharat Biotech signs contract manufacturing deal for Covaxin with Gujarat consortium

The CNY900 million ($130.4 million) worth first phase has involved the construction of an array of advanced manufacturing plants to meet global and China good manufacturing practice standards.

Everest Medicines commissions mRNA vaccine production plant in Jiashan

Everest Medicines commissions mRNA vaccine production plant in Jiashan. Photo courtesy of Everest Medicines.

Rogers Yongqing Luo — Everest Medicines CEO said: “The COVID-19 pandemic is still raging globally, and the evolving variants bring significant challenges.

“We are actively advancing the development of mRNA COVID-19 vaccines to better protect people’s health and support China’s national public policy.

See also  Tension peaks as Chinese warplanes swarm Taiwan airspace ahead of key military drills

“The startup of our mRNA vaccine factory is a key step in our strategic goal of having a complete industrial value chain of research, clinical development, manufacturing and commercialization.

“We will continue to develop our clinically-validated mRNA technology platform across a wide range of diseases, such as infectious diseases and cancer, while preparing for commercialization, and accelerating our path to becoming a fully-integrated biopharmaceutical company.”

See also  Alibaba's new hotel runs on robot hospitality

In September 2021, Everest Medicines partnered with Providence Therapeutics to advance mRNA vaccines and therapies.

Everest Medicines anticipates achieving long-term growth momentum through the localization of its advanced mRNA technology platform.

The Chinese biopharma company is developing EVER-COVID19-M1.2, an Omicron-based bivalent booster candidate, and anticipates beginning clinical studies in China and other Everest Medicines territories of interest in 2023.

Everest Medicines said it has achieved the preclinical proof-of-concept milestone for its mRNA rabies vaccine program.

CATEGORIES
TAGS
Share This